阿尼卡疗法 ANIK 深 沪
已收盘 08-15 16:00:00 美东时间
8.83
+0.190
+2.20%
华盛通- 最 高9.09
- 今 开8.75
- 成交量 9.52万股
- 最 低 8.75
- 昨 收 8.64
- 总市值 1.27亿
- 52周最高 26.48
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 7.8701
- 委 比 65.59%
- 总股本 1434.14万
- 历史最高 75.715
- 量 比 0.71
- 振 幅 3.94%
- 历史最低 5.24
- 每 手 1
- 风险率 5.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
Anika Therapeutics shares are trading lower after the company announced the topline results from the Hyalofast trial missed its statistically significant endpoints.
Anika Therapeutics shares are trading lower after the company announced the top...
07-30 23:57
Anika outlines 10%–20% commercial channel growth for 2026–2027 amid Hyalofast FDA timeline adjustment
Earnings Call Insights: Anika Therapeutics (ANIK) Q2 2025 Management View Cheryl Renee Blanchard, President and CEO, highlighted a “meaningful quarter for Anika, including a significant clinical updat...
07-30 22:53
Anika Therapeutics Q2 Adj. EPS $(0.13) Beats $(0.17) Estimate, Sales $28.22M Beat $27.70M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 176.47 percent decrease over earnings of $0.17 per share
07-30 19:16
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
Anika Therapeutics announced top-line results from its U.S. pivotal trial of Hyalofast, a hyaluronic acid scaffold used for cartilage repair. While Hyalofast showed consistent improvements over microfracture in pain and function measures, it did not meet the pre-specified co-primary endpoints for statistical significance. However, it demonstrated statistically significant improvements in key secondary endpoints and other measures aligned with pri...
07-30 11:00
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
The NEW DAY clinical trial compared ILUVIEN® to aflibercept for treating diabetic macular edema (DME) over 18 months. The primary endpoint of the mean number of supplemental aflibercept injections did not reach statistical significance between the ILUVIEN (2.4) and aflibercept (2.5) arms. However, a post-hoc analysis showed ILUVIEN significantly reduced the number of injections (1.8 vs. 2.5, p=0.029). ILUVIEN also met the secondary endpoint, with...
07-23 10:50
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
Anika Therapeutics, Inc. will release its Q2 2025 financial results before the market opens on July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The call can be accessed via 1-800-717-1738 (domestic) or 1-646-307-1865 (international) using conference ID 48251. A live audio webcast and presentation materials will be available on the Investor Relations section of Anika's website, www.anika....
07-16 20:01
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
The CEO of ANI Pharmaceuticals, Inc., Nikhil Lalwani, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism in Boston on July 8, 2025. The company, which focuses on developing innovative therapeutics in rare diseases, generics, and brands, announced the event in a press release.
07-02 10:50
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
ANI Pharmaceuticals presented preclinical data on Purified Cortrophin Gel in a murine collagen-induced arthritis model at the 2025 EULAR Congress. The study showed that the gel reduced joint swelling and inflammatory cytokines without causing bone loss. This research, led by Maripat Corr, MD, and Nancy Lane, MD, provides new insights into the mechanism of action of Cortrophin Gel, a prescription drug for treating rheumatoid arthritis. The finding...
06-12 11:00
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. granted 2,500 non-statutory stock options to a newly hired non-executive employee, with an exercise price of $11.45 per share. The options vest annually over three years and expire after 10 years. The grant was made under the 2021 Inducement Plan, approved by the compensation committee, as part of the employee's compensation. Anika is a global leader in osteoarthritis pain management and regenerative solutions, headquarte...
06-05 21:00
